1
|
Banerjee S, Leary A, Stewart J, Dewan M, Lheureux S, Clamp A, Ray-Coquard I, Selle F, Gourley C, Glasspool R, Bowen R, Attygalle A, Vroobel K, Tunariu N, Wilkinson K, Toms C, Natrajan R, Bliss J, Lord C, Porta N. 34O ATR inhibitor alone (ceralasertib) or in combination with olaparib in gynaecological cancers with ARID1A loss or no loss: Results from the ENGOT/GYN1/NCRI ATARI trial. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.100814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/27/2023] Open
|
2
|
Ferro R, Carroll A, Mendes-Pereira A, Reen V, Roxanis I, Annunziato S, Jonkers J, Liv N, Alexander J, Quist J, Pardo M, Roumeliotis T, Choudhary J, Weekes D, Marra P, Natrajan R, Grigoriadis A, Haider S, Lord C, Tutt A. The anion channel GPR89 is a novel oncogene associated with tumour specific dependency in breast cancer. Eur J Cancer 2022. [DOI: 10.1016/s0959-8049(22)00934-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
3
|
Stewart J, Baxter J, Zatreanu D, Brough R, Song F, Konde A, Krastev D, Alexander J, Natrajan R, Pettitt S, Banerjee S, Lord C. 3P Identification of novel biomarkers of response to ATR inhibitors in ARID1A mutant ovarian clear cell carcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
4
|
Banerjee S, Leary A, Lheureux S, Stewart J, Attygalle A, Vroobel K, Gill S, Ali Z, Tai J, Toms C, Natrajan R, Lord C, Porta N, Bliss J. 815TiP ENGOT/GYN1/NCRI: ATR inhibitor in combination with olaparib in gynaecological cancers with ARID1A loss or no loss (ATARI). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
5
|
Khalique S, Naidoo K, Attygalle A, Kriplani D, Daley F, Jones T, Fenwick K, Lord C, Banerjee S, Natrajan R. PO-457 Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.964] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
6
|
Geyer FC, Ng CK, Piscuoglio S, Wen YH, Wen HC, Pareja F, Eberle CA, Burke KA, Lim RS, Natrajan R, Mariani O, Brogi E, Norton L, Vincent-Salomon A, Weigelt B, Reis-Filho JS. Abstract P1-05-03: The genomic landscape of breast metaplastic carcinoma. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-05-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Metaplastic breast carcinoma (MBC) is a rare histologic type of triple-negative breast cancer (TNBC), characterized by the presence of cells displaying squamous and/or mesenchymal differentiation. The transcriptomic profiles of MBCs have been reported to vary according to the type of metaplastic elements. The somatic genetic alterations that underpin this breast cancer subtype remain to be fully characterized. Here we sought to define the genomic landscape of MBCs, whether different subtypes of MBC would be driven by distinct constellations of genetic alterations, and to investigate functionally the impact of mutations affecting WNT pathway genes using non-malignant breast epithelial cells.
Methods: Thirty-five MBCs were retrieved from the pathology department of the authors' institutions and classified into the MBC histologic subtypes. All but one of the MBCs were of triple-negative phenotype. DNA was extracted from microdissected tumor-normal pairs and subjected to whole-exome sequencing. Somatic genetic alterations were identified using state-of-the-art bioinformatics algorithms. The genomic profiles of MBCs were compared to those of 69 common type TNBCs from The Cancer Genome Atlas. Overall mutation rates were compared using the Mann Whitney U test, and the frequency of mutations in each gene was compared using Fisher's exact test. RNA was extracted from a subset of MBCs and subjected to WNT signaling pathway activation analysis with the RT2 Profiler PCR Array. Triple-negative non-malignant breast epithelial cells (MCF10A and MCF12A) and cancer cell lines were utilized for 2D and 3D functional studies.
Results: Whole-exome analysis revealed that MBCs displayed a median of 103 (15-344) somatic mutations, which did not differ from the median number of somatic mutations in common type TNBCs (76, range 14-233). The most frequent recurrently mutated cancer genes included TP53 (69%) and PIK3CA (29%). MBCs more frequently harbored mutations in PI3K pathway genes than common type TNBCs (57% vs 22%, P<0.05), including mutations affecting PIK3CA (29% vs 7%), PIK3R1 (11% vs 0) and PTEN (11% vs 1%). MBCs also more frequently harbored mutations affecting WNT signaling pathway genes (46% vs 26%, P<0.05), including AXIN1 (6% vs 1%), WNT5A (6% vs 0) and APC (3% vs 0). MBC subtype analysis revealed that PIK3CA mutations were only detected in non-chondroid MBCs (53% vs 0), CHERP mutations were only found in chondroid MBCs (25% vs 0), whereas USP5 mutations only found in squamous MBCs (33% vs 0). MBCs with somatic mutations in WNT pathway genes had significantly higher WNT pathway activation than MBCs lacking mutations in these genes (P=0.0244). Consistent with the mesenchymal phenotype frequently exhibited by MBCs, in vitro experiments provided functional evidence that aberrant WNT pathway activation induces an epithelial-to-mesenchymal transition (EMT) phenotype, with downregulation of epithelial markers and upregulation of EMT transcriptional inducers.
Conclusions: MBCs are significantly enriched for mutations affecting PI3K and WNT pathways, highlighting the importance of the dysregulation of the WNT pathway in MBC carcinogenesis. Moreover, our findings suggest that specific mutations are significantly associated with distinct histologic subtypes of MBCs.
Citation Format: Geyer FC, Ng CK, Piscuoglio S, Wen YH, Wen H-C, Pareja F, Eberle CA, Burke KA, Lim RS, Natrajan R, Mariani O, Brogi E, Norton L, Vincent-Salomon A, Weigelt B, Reis-Filho JS. The genomic landscape of breast metaplastic carcinoma [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-05-03.
Collapse
Affiliation(s)
- FC Geyer
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - CK Ng
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - S Piscuoglio
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - YH Wen
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - H-C Wen
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - F Pareja
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - CA Eberle
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - KA Burke
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - RS Lim
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - R Natrajan
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - O Mariani
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - E Brogi
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - L Norton
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - A Vincent-Salomon
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - B Weigelt
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - JS Reis-Filho
- Memorial Sloan Kettering Cancer Center, New York, NY; The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| |
Collapse
|
7
|
Mohd Noor A, Maguire S, Watkins J, Quist J, Mirza H, Tutt A, Gillett C, Natrajan R, Grigoriadis A. Abstract P1-05-14: Copy number aberration-induced gene breakage analysis identifies recurrent FOXP1 fusions in breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-05-14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Genomic instability is a critical feature of breast cancers, which manifests in genome-wide copy number aberrations (CNA), often causing “gene breakage” and the generation of fusion genes. We aimed to identify aborted transcripts with underlying CNAs and to investigate the molecular landscape of breast cancers harbouring such events.
Methods: A walking student's t-test algorithm was applied to Affymetrix Exon 1.0ST array data of 123 breast cancers to identify regions of aborted transcription and overlaid with DNA breakpoints derived from matched Affymetrix SNP6 ASCAT-segmented copy number. Aborted transcripts were investigated as potential fusion gene partners through RNA-seq analysis of 151 breast cancer samples (TCGA) and 51 breast cancer cell lines (BCCL) using ChimeraScan. Clinical correlates were established for clinicopathological features, genomic instability measures, and gene expression-based molecular classifiers including PAM50, TNBCtype, IntClust subtypes and immune signatures.
Results: One hundred and six genes with recurrent CNA-induced aborted transcription were identified. Aborted transcription showed hormone receptor subtype-specificity for 7 genes (nTNBC=1, nNon-TNBC=6) and was less prevalent in samples of IntClust 2 and IntClust 4 subtypes (p: 0.0043, 0.0011). Aborted transcripts were more frequently observed in samples with greater copy-neutral loss of heterozygosity (p=0.012), while aborted transcription of 54/106 genes significantly affected enrichment of 27 tumor-infiltrating lymphocyte subpopulations.14 aborted transcripts were found as a fusion gene with one partner in RNA-seq of TCGA and BCCL, while 19 were involved in multiple fusion events (range=1-6, median=2). Nine of 106 genes displayed gene breakage and fusion events exclusively in samples with an enriched tandem duplication phenotype. Notably, FOXP1, localised to a tumour suppressor locus at 3p14.1, reported the highest number of fusion configurations (n=6) with concurrent aborted transcription across all RNA-seq datasets (nPRADA=9, nTCGA=38, nBCCL=6).
Conclusion: CNA-induced gene breakage affects the molecular landscape of breast cancers and is linked with many genomic configurations of interest including copy-neutral loss of heterozygosity and tandem duplications. In particular, the role of recurrent gene fusions of the tumour suppressor, FOXP1, in tumourigenesis warrants further investigation.
Citation Format: Mohd Noor A, Maguire S, Watkins J, Quist J, Mirza H, Tutt A, Gillett C, Natrajan R, Grigoriadis A. Copy number aberration-induced gene breakage analysis identifies recurrent FOXP1 fusions in breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-05-14.
Collapse
Affiliation(s)
- A Mohd Noor
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - S Maguire
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - J Watkins
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - J Quist
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - H Mirza
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - A Tutt
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - C Gillett
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - R Natrajan
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| | - A Grigoriadis
- Cancer Bioinformatics, Guy's Hospital, King's College London, London, United Kingdom; Breast Cancer Now Research Centre, Institute of Cancer Research, London, United Kingdom; Breast Cancer Now Research Unit, Guy's Hospital, King's College London, London, United Kingdom; King's College London, London, United Kingdom
| |
Collapse
|
8
|
Noor AM, Maguire S, Watkins J, Quist J, Mirza H, Ougham K, Tutt A, Gillett C, Natrajan R, Grigoriadis A. The characterisation of potential fusion genes in breast cancer. Eur J Cancer 2016. [DOI: 10.1016/s0959-8049(16)61097-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Piscuoglio S, Ng CKY, Cowell CF, Mariani O, Martelotto L, Natrajan R, Lim RS, Maher CA, Vincent-Salomon A, Weigelt B, Reis-Filho JS. Abstract P6-03-10: Genomic and transcriptomic heterogeneity in metaplastic breast carcinomas. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p6-03-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Metaplastic breast carcinoma (MBC) is a rare form of triple-negative breast cancer (TNBC), accounting for approximately 0.2%-5% of all invasive breast cancers. These tumors are characterized by the presence of neoplastic cells displaying differentiation towards squamous epithelium or mesenchymal elements. MBCs are reported to have an aggressive clinical behavior, to exhibit a worse prognosis and to respond less frequently to conventional chemotherapy regimens than common forms of TNBCs. In this study, we sought to define whether morphologically distinct subgroups of MBCs would be underpinned by distinct gene expression or copy number profiles, and whether MBCs, akin to other special histologic types of TNBC (e.g. secretory carcinoma and adenoid cystic carcinoma), would be underpinned by a highly recurrent fusion gene.
Methods: RNA and DNA samples were extracted from microdissected frozen MBCs (5 squamous, 5 spindle and 7 chondroid) and subjected to gene expression profiling using the Illumina Human HT-12 v4 platform and gene copy number profiling using the Affymetrix Human SNP 6.0 arrays, respectively. Genes differentially expressed between MBC subtypes were identified using SAM, and functional annotation of these genes was performed using Ingenuity Pathway Analysis. Intrinsic molecular subtypes were determined using the PAM50 and claudin-low intrinsic gene lists. In addition, all cases were subjected to paired-end massively parallel RNA-sequencing (Illumina GAIIx). Putative expressed fusion transcripts were identified using a validated algorithm (i.e. ChimeraScan), and confirmed by means of RT-PCR.
Results: MBCs with spindle cell morphology were all classified as of claudin-low intrinsic subtype, whereas MBCs with chondroid or squamous cell metaplasia were classified as of normal breast-like, basal-like or claudin-low subtypes, suggesting that these morphologic subgroups are heterogeneous. Unsupervised analysis of microarray and RNA-sequencing gene expression data further demonstrated that MBCs with spindle cell differentiation displayed distinctive transcriptomic profiles, and formed clusters distinct from those enriched for MBCs with chondroid and squamous cell metaplasia. MBCs with spindle cell morphology preferentially expressed regulators of epithelial-to-mesenchymal transition including lower expression of E-cadherin and EpCAM. At the genomic level, MBC subtypes displayed patterns of gene copy number alterations similar to those of common forms of TNBCs from The Cancer Genome Atlas, and no significant differences were found among the distinct MBC subtypes. Nine in-frame fusion genes, TBL1XR1-PIK3CA, WAPL-CDHR1, MAP2K3-HMGCLL, PARG-BMS1, FN1-ICAM1, TNKS1BP1-SPARC, AAK1-ARNT2, MBTPS1-TCEANC2 and PSMA6-SHMT1 were identified and validated in the index cases, however none of these was found to be recurrent in the cases analyzed in this study.
Conclusion: MBC subtypes, despite harboring similar patterns of gene copy number alterations, display significant transcriptomic differences, which may account for their distinct histologic features. Our findings also demonstrate that unlike other histologic special types of TNBC, MBCs are not underpinned by a highly recurrent expressed fusion gene.
Citation Format: Piscuoglio S, Ng CKY, Cowell CF, Mariani O, Martelotto L, Natrajan R, Lim RS, Maher CA, Vincent-Salomon A, Weigelt B, Reis-Filho JS. Genomic and transcriptomic heterogeneity in metaplastic breast carcinomas. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P6-03-10.
Collapse
Affiliation(s)
- S Piscuoglio
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - CKY Ng
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - CF Cowell
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - O Mariani
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - L Martelotto
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - R Natrajan
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - RS Lim
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - CA Maher
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - A Vincent-Salomon
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - B Weigelt
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| | - JS Reis-Filho
- Memorial Sloan Kettering Cancer Center, NY, NY; Institut Curie, Paris, France; The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; The Genome Institute, Washington University School of Medicine, St Louis, MO
| |
Collapse
|
10
|
Carvalho D, Taylor K, Burford A, Nowak I, Mackay A, Vinci M, Bjerke L, Molinari V, Nandhabalan M, Ingram W, Jury A, Natrajan R, Jones D, Pfister S, Shats L, Moore A, Jacques T, Popov S, Jones C. HG-09 * INFANTILE GLIOBLASTOMA WITH SARCOMATOUS HISTOLOGY DRIVEN BY ETV6:NTRK3 FUSIONS ARE SENSITIVE TO TRK INHIBITION BY PHA-848125. Neuro Oncol 2015. [DOI: 10.1093/neuonc/nov061.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
11
|
Maguire S, Leonidou A, Wai P, Marchio C, Ng C, Weigelt B, Sapino A, Vincent-Salomon A, Reis-Filho J, Natrajan R. 575 SF3B1 mutations are associated with alternative splicing in ER-positive breast cancer. Eur J Cancer 2014. [DOI: 10.1016/s0959-8049(14)70701-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
12
|
Garcia-Murillas I, Pearson A, Lambros M, Natrajan R, Segal C, Dowsett M, Turner NC. Abstract P2-08-01: Analysis of PIK3CA mutation abundance in primary breast cancer with droplet digital PCR identifies frequent sub-clonal PIK3CA mutations in ER negative and / or HER2 positive breast cancer. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p2-08-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: PIK3CA is the single most commonly mutated gene in breast cancer, with highest incidence reported in ER positive and HER2 negative breast cancer. Substantial data now suggests that breast cancers show intra-tumoural genetic heterogeneity, with apparently clonal tumours composed of multiple populations of tumour cells that, in addition to the founder genetic events common to all cells, harbour private genetic alterations. Tumours with mutations that are sub-clonal may respond less well to therapies targeting these mutations than cancers with clonal mutations. To assess how frequently PIK3CA mutations are clonal founder mutations, or may be subclonal, we assessed the abundance on PIK3CA mutation using digital PCR.
Methods: DNA was extracted from frozen sections of 119 primary breast cancers, following macrodissection to achieve tumour cell content of >70%. PIK3CA mutations c.1624G>A (E542K), c.1633G>A (E545K), c.3140A>T (H1047L) and c.3140A>G (H1047R) were assessed by droplet digital PCR on a BioRad QX100 system. Exon 9 mutation assays were optimised to not amplify the PIK3CA pseudogene. Mutational abundance was calculated from the Poisson distribution, expressed as the portion of PIK3CA DNA in the sample that was mutant, and compared between breast cancer subtypes. A mutational abundance of <20% was predefined to represent low abundance mutation, that may be subclonal.
Results: PIK3CA mutations were detected with abundance ranging from 80.4% to 0.0063%, with 26 cancers with an abundance >20% and 19 cancers with low abundance <20% (5 cancers with abundance 1-20%, and 14 cancer with abundance <1%). There was highly correlation between repeat experiments r2 = 0.98, p<0.0001, with 100% concordance for low abundance mutations in repeat analysis. High abundance mutations were numerically more common in ER positive HER2 negative cancers (18/65, 28%) than HER2 positive or triple negative (TN) cancers (7/54, 14% p = 0.07 Fishers exact test). Conversely, low abundance mutations were less common in ER positive HER2 negative cancers (4/65, 6%) than in HER2 positive or TN cancers (10/54, 19% p = 0.047). In cancers with a detectable PIK3CA mutation, mutational abundance was higher in ER positive cancer than ER negative cancers (p = 0.023 Mann-Whitney U test), and higher in ER positive HER2 negative cancers compared to HER2 positive or TN cancers (p = 0.0024). In ER positive HER2 negative cancers 82% (18/22) mutations were of high abundance, and likely clonal, whereas in TN or HER2 positive cancers 39% (7/18, p = 0.009) were of high abundance.
Conclusion: Our data suggests that hotspot PIK3CA mutations are frequently of low abundance in HER2 positive or TN breast cancer, and may be subclonal. However, we cannot exclude the possibility that these findings represent contamination. If confirmed on an independent data set, our data suggest that identification of mutational abundance may be an important component of PIK3CA mutation assessment and the potential targeting of these mutations with PI3 kinase inhibitors.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P2-08-01.
Collapse
Affiliation(s)
- I Garcia-Murillas
- Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - A Pearson
- Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - M Lambros
- Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - R Natrajan
- Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - C Segal
- Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - M Dowsett
- Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| | - NC Turner
- Institute of Cancer Research, London, United Kingdom; Royal Marsden Hospital, London, United Kingdom
| |
Collapse
|
13
|
Piscuoglio S, Ng CKY, Martelotto LG, Cowell CF, Natrajan R, Bidard FC, Wilkerson PM, Mariani O, Vincent-Salomon A, Weigelt B, Reis-Filho JS. Abstract P4-04-08: Genomic and transcriptomic characterization of papillary carcinomas of the breast. Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p4-04-08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: Papillary carcinomas (PCs) are a rare (<1%) special histological type of breast cancer that often affects postmenopausal women, and has an overall favorable outcome. Based on their histological characteristics, these tumors are classified into three different subtypes, namely encapsulated papillary carcinomas (EPC), solid papillary carcinomas (SPC) and invasive papillary carcinomas (IPC). In this study, we sought i) to investigate whether PCs constitute a molecular entity distinct from grade- and ER-matched invasive ductal carcinomas of no special type (IDC-NST) at the transcriptomic level, ii) to investigate whether EPC, SPC and IPC display distinct transcriptomic profiles, iii) to characterize the repertoire of copy number alterations in the different subtypes of PC, and iv) to identify recurrent fusion genes that may be potential drivers of this disease.
Material and methods: DNA and RNA were extracted from microdissected PCs (4 SPCs, 5 IPCs and 7 EPCs) and grade- and ER-matched IDC-NSTs (RNA only). 16 PCs and 16 grade- and ER-matched IDC-NSTs were subjected to gene expression profiling using the Illumina Human HT-12 v4 platform. Genes differentially expressed between the PC subtypes were identified using SAM, and functional annotation of these genes was performed using DAVID. Intrinsic molecular subtypes were determined using the PAM50 single sample predictor. Copy number profiling was performed using Affymetrix Human SNP 6.0 arrays with DNA extracted from 16 PCs. In addition, 8 PCs (3 IPCs, 3 EPCs, 2 SPCs) were subjected to paired-end massively parallel RNA sequencing (Illumina GAIIx). Putative expressed fusion transcripts were identified using validated algorithms (i.e. deFuse and Chimerascan), and confirmed by reverse transcription PCR.
Results: PCs were preferentially of histological grade I/II (82%) and ER-positive (100%). Unsupervised analysis revealed that PC subtypes show a high degree of similarity at the transcriptomic level, and form clusters distinct from grade- and ER-matched IDC-NSTs. Compared with IDC-NSTs, PCs displayed reduced expression of genes related to cell motility, adhesion and extracellular matrix. PAM50 subtyping classified 87.5%, 50% and 100% of EPCs, SPCs and IPCs as of luminal subtypes, respectively. 12.5% of EPCs were classified as of basal-like subtype, and 50% of SPCs as of HER2-enriched subtype. At the genomic level, PC subtypes displayed similar patterns of gene copy number aberrations. Five in-frame fusion genes, USF1-CCDC38, MDC1-SFTA2, DLD-LMBR1, PDCL-DENND1A and SUGT1-NOL6, were identified and validated in PCs, however none of these were recurrent in the cases included in this study.
Conclusion: Our results demonstrate that the majority of PCs are of luminal subtype, and support the contention that at the transcriptomic level, PCs are distinct from grade- and ER-matched IDC-NSTs. Our findings also demonstrate that unlike some other histological special types of breast cancer, PCs are not underpinned by a highly recurrent expressed fusion gene.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-04-08.
Collapse
Affiliation(s)
- S Piscuoglio
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - CKY Ng
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - LG Martelotto
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - CF Cowell
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - R Natrajan
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - F-C Bidard
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - PM Wilkerson
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - O Mariani
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - A Vincent-Salomon
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - B Weigelt
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| | - JS Reis-Filho
- Memorial Sloan-Kettering Cancer Center, New York, NY; The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France
| |
Collapse
|
14
|
Shiu KK, Wetterskog D, Mackay A, Natrajan R, Lambros M, Sims D, Bajrami I, Brough R, Frankum J, Sharpe R, Marchio C, Horlings H, Reyal F, van der Vijver M, Turner N, Reis-Filho JS, Lord CJ, Ashworth A. Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. Oncogene 2013; 33:619-31. [PMID: 23334330 DOI: 10.1038/onc.2012.625] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2012] [Revised: 11/04/2012] [Accepted: 11/14/2012] [Indexed: 12/30/2022]
Abstract
Overexpression of the receptor tyrosine kinase ERBB2 (also known as HER2) occurs in around 15% of breast cancers and is driven by amplification of the ERBB2 gene. ERBB2 amplification is a marker of poor prognosis, and although anti-ERBB2-targeted therapies have shown significant clinical benefit, de novo and acquired resistance remains an important problem. Genomic profiling has demonstrated that ERBB2+ve breast cancers are distinguished from ER+ve and 'triple-negative' breast cancers by harbouring not only the ERBB2 amplification on 17q12, but also a number of co-amplified genes on 17q12 and amplification events on other chromosomes. Some of these genes may have important roles in influencing clinical outcome, and could represent genetic dependencies in ERBB2+ve cancers and therefore potential therapeutic targets. Here, we describe an integrated genomic, gene expression and functional analysis to determine whether the genes present within amplicons are critical for the survival of ERBB2+ve breast tumour cells. We show that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ERBB2 oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies. These include an addiction to the transcription factor gene TFAP2C when it is amplified and overexpressed, suggesting that TFAP2C represents a genetic dependency in some ERBB2+ve breast cancer cells.
Collapse
Affiliation(s)
- K-K Shiu
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - D Wetterskog
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - A Mackay
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - R Natrajan
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - M Lambros
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - D Sims
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - I Bajrami
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - R Brough
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - J Frankum
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - R Sharpe
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - C Marchio
- Department of Biomedical Sciences and Human Oncology, University of Turin, Turin, Italy
| | - H Horlings
- Department of Pathology, Academic Medical Centre, Amsterdam, The Netherlands
| | - F Reyal
- Department of Pathology, Academic Medical Centre, Amsterdam, The Netherlands
| | - M van der Vijver
- Department of Pathology, Academic Medical Centre, Amsterdam, The Netherlands
| | - N Turner
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - J S Reis-Filho
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - C J Lord
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| | - A Ashworth
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, UK
| |
Collapse
|
15
|
Ng CKY, Gauthier A, Mackay A, Lambros MBK, Rodrigues DN, Arnoud L, Lacroix-Triki M, Penault-Llorca F, Baranzelli MC, Sastre-Garau X, Lord CJ, Zvelebil M, Mitsopoulos C, Ashworth A, Natrajan R, Weigelt B, Delattre O, Cottu P, Reis-Filho JS, Vincent-Salomon A. Abstract PD05-08: Genomic characterisation of invasive breast cancers with heterogeneous HER2 gene amplification. Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-pd05-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Aims: HER2 gene amplification is observed in up to 15% of breast carcinomas. In a rare subset of breast cancers classified as HER2-positive by immunohistochemistry and in situ hybridisation, HER2 overexpression and gene amplification are restricted to a subset of >30% but not all cancer cells. Here we sought to characterise the repertoire of gene copy number aberrations and somatic mutations in the HER2-positive and HER2-negative components of cases with heterogeneous HER2 overexpression and gene amplification.
Material and methods: Cases diagnosed as HER2 positive but with >30% but <100% of cells displaying HER2 overexpression were retrieved from the authors' institutions. HER2 heterogeneity status was re-assessed using immunohistochemistry and chromogenic and/ or fluorescence in situ hybridisation. For cases with confirmed HER2 gene amplification heterogeneity, HER2-positive and HER2-negative components were microdissected from tissue sections stained with the Herceptest antibody. DNA samples extracted from both components of each case were subjected to microarray-based comparative genomic hybridisation (aCGH), using a 32K BAC array platform with 50Kb resolution. The HER2-positive and HER2-negative components of cases with frozen material were also subjected to massively parallel targeted exome sequencing.
Results: Twelve cases yielded sufficient DNA for aCGH analysis. Tumours were preferentially ER positive (83%) and of histological grade 3 (67%). The HER2-positive and HER2-negative components of all cases shared most of the copy number aberrations. A pairwise comparison of the genomic profiles of the two components from each case revealed that in ten of the twelve cases, copy number aberrations in addition to 17q12 amplification encompassing the HER2 gene locus were restricted to one of the two components. Exome sequencing of two cases suggested that the HER2-positive and HER2-negative components from each case harboured >30 somatic mutations in common, including identical TP53 somatic mutations in both components of each case. The HER2-negative component of one of the cases displayed a somatic mutation in NRG2, an ERBB receptor ligand, and the HER2-negative component of the other case harboured a mutation in PTTG1IP, a proto-oncogene with putative oestrogen receptor elements.
Conclusions: Our results demonstrate that in HER2-positive breast cancers with heterogeneous HER2 gene amplification, the HER2-positive and HER2-negative components are clonally related. The distinct genomic profiles of HER2-positive and HER2-negative components, however, suggest that, at least in some of these cases, HER2 amplification may constitute a relatively late event in tumour evolution. Exome sequencing revealed mutations restricted to the HER2-negative components of HER2-positive tumours with heterogeneous HER2 overexpression/gene amplification, which may constitute potential drivers in the absence of HER2 overexpression/gene amplification.
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr PD05-08.
Collapse
Affiliation(s)
- CKY Ng
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - A Gauthier
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - A Mackay
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - MBK Lambros
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - DN Rodrigues
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - L Arnoud
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - M Lacroix-Triki
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - F Penault-Llorca
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - MC Baranzelli
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - X Sastre-Garau
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - CJ Lord
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - M Zvelebil
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - C Mitsopoulos
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - A Ashworth
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - R Natrajan
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - B Weigelt
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - O Delattre
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - P Cottu
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - JS Reis-Filho
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| | - A Vincent-Salomon
- The Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, United Kingdom; Institut Curie, Paris, France; CRB Ferdinand Cabanne, Centre Georges François Leclerc, Dijon, France; Institut Claudius Regaud, Toulouse, France; Centre Jean Perrin, Clermont-Ferrand, France; Centre Oscar Lambret, Lille, France
| |
Collapse
|
16
|
Dedes KJ, Wilkerson P, Wetterskog D, Lambros MB, Natrajan R, Tan D, Lord CJ, Kaye SB, Ashworth A, Reis-Filho JS. Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer. Geburtshilfe Frauenheilkd 2011. [DOI: 10.1055/s-0031-1286501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|
17
|
Dedes KJ, Wetterskog D, Mendes-Pereira AM, Vatcheva R, Natrajan R, Lambros MB, Lord CJ, Ashworth A, Reis-Filho JS. Preclinical evaluation of PARP inhibition as a treatment for endometrioid endometrial carcinomas. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
|
19
|
Turner N, Turner N, Lambros M, Horlings H, Horlings H, Pearson A, Sharpe R, Mackay A, Natrajan R, Geyer F, van Kouwenhove M, Kreike B, Ashworth A, van de Vijver M, van de Vijver M, Reis-Filho J. Integrative Molecular Profiling of Triple Negative Breast Cancers Identifies Potential Therapeutic Targets Including Amplifications of FGFR2. Cancer Res 2009. [DOI: 10.1158/0008-5472.sabcs-09-3147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Triple negative breast cancers (TNBCs) have a relatively poor prognosis emphasising the need to identify new subtype specific target therapies. Based on the concept of oncogene addiction, we searched for potential therapeutic targets by identifying genes consistently over-expressed when amplified in TNBC. Fifty six TNBCs were subjected to high resolution tiling path microarray-based comparative genomic hybridisation (aCGH); out of these cases, 24 were also subjected to genome-wide microarray-based mRNA expression analysis. TNBCs showed a high level of genetic instability, with recurrent regions of amplification (>4 copies) included multiple regions on 1q and 8q, 3q25, 10p14, 10q26, 13q34, 15q26 and 19q12-19q13. Integration of aCGH and expression data revealed 38 genes that were significantly overexpressed when amplified. This list includes known oncogenes and potential therapeutic targets, such as MCL1 (1q21.2), FGFR2 (10q26.3), BUB3 (10q26.3), RAB20 (13q34), PKN1 (19p13.12), and NOTCH3 (19p13.12). To validate FGFR2 as a therapeutic target, we screened a panel of cell lines, by western blotting and aCGH, and identified two TNBC cell lines with FGFR2 amplification. In these cell lines FGFR2 was constitutively active in a ligand independent manner, and RNA interference-mediated silencing of FGFR2 selectively decreased survival of cell lines harbouring FGFR2 amplification. Likewise FGFR2 amplified cell lines were highly sensitive to FGFR tyrosine kinase inhibitor PD173074 (IC50 <20nM). Treatment with PD173074 induced apoptosis in amplified cell lines, as did treatment with PI3 kinase inhibitors LY294002 and BEZ-235 suggesting that apoptosis resulted from inhibition of AKT signalling. Examination of publically available CGH data sets confirmed FGFR2 amplification in 4% (5/124 95%CI 1.3-9.2%) of TNBC, with no cases of FGFR2 amplification in other subtypes (0/150, p=0.02). Our results suggest that FGFR2 amplification is a therapeutic target in a small subset of TNBCs.
Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 3147.
Collapse
Affiliation(s)
- N. Turner
- 1The Institute of Cancer Research, United Kingdom
| | - N. Turner
- 2Royal Marsden Hospital NHS Trust, United Kingdom
| | - M. Lambros
- 1The Institute of Cancer Research, United Kingdom
| | | | - H. Horlings
- 4The Netherlands Cancer Institute, The Netherlands
| | - A. Pearson
- 1The Institute of Cancer Research, United Kingdom
| | - R. Sharpe
- 1The Institute of Cancer Research, United Kingdom
| | - A. Mackay
- 1The Institute of Cancer Research, United Kingdom
| | - R. Natrajan
- 1The Institute of Cancer Research, United Kingdom
| | - F. Geyer
- 1The Institute of Cancer Research, United Kingdom
| | | | - B. Kreike
- 4The Netherlands Cancer Institute, The Netherlands
| | - A. Ashworth
- 1The Institute of Cancer Research, United Kingdom
| | | | | | | |
Collapse
|
20
|
Marchiò C, Natrajan R, Shiu KK, Lambros MBK, Rodriguez‐Pinilla SM, Tan DSP, Lord CJ, Hungermann D, Fenwick K, Tamber N, Mackay A, Palacios J, Sapino A, Buerger H, Ashworth A, Reis‐Filho JS. The genomic profile of
HER2
‐amplified breast cancers: the influence of ER status. J Pathol 2008; 216:399-407. [DOI: 10.1002/path.2423] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- C Marchiò
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
- Department of Biomedical Sciences and Human Oncology, University of Turin, Italy
| | - R Natrajan
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | - KK Shiu
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | - MBK Lambros
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | | | - DSP Tan
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | - CJ Lord
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | | | - K Fenwick
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | - N Tamber
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | - A Mackay
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | - J Palacios
- Hospital Universitario Virgen del Rocío, Seville, Spain
| | - A Sapino
- Department of Biomedical Sciences and Human Oncology, University of Turin, Italy
| | - H Buerger
- Institute of Pathology, Paderborn, Germany
| | - A Ashworth
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| | - JS Reis‐Filho
- The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK
| |
Collapse
|
21
|
Marchiò C, Iravani M, Natrajan R, Lambros MB, Savage K, Tamber N, Fenwick K, Mackay A, Senetta R, Di Palma S, Schmitt FC, Bussolati G, Ellis LO, Ashworth A, Sapino A, Reis-Filho JS. Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast. J Pathol 2008; 215:398-410. [PMID: 18484683 DOI: 10.1002/path.2368] [Citation(s) in RCA: 124] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Pure invasive micropapillary carcinoma (MPC) is a special histological type that accounts for 0.7-3% of all breast cancers. MPC has a distinctive growth pattern and a more aggressive clinical behaviour than invasive ductal carcinomas of no special type (IDC-NSTs). To define the molecular characteristics of MPCs, we profiled a series of 12 MPCs and 24 grade and oestrogen receptor (ER)-matched IDC-NSTs using high-resolution microarray comparative genomic hybridization (aCGH). In addition, we generated a tissue microarray containing a series of 24 MPCs and performed immunohistochemical analysis with ER, PR, Ki-67, HER2, CK5/6, CK14, CK17, EGFR, topoisomerase-IIalpha, cyclin D1, caveolin-1, E-cadherin, and beta-catenin antibodies. In situ hybridization probes were employed to evaluate the prevalence of amplification of HER2, TOP2A, EGFR, CCND1, MYC, ESR1, and FGFR1 genes. aCGH analysis demonstrated that MPCs significantly differed from IDC-NSTs at the genomic level. Gains of 1q, 2q, 4p, 6p, 6q23.2-q27, 7p, 7q, 8p, 8q, 9p, 10p, 11q, 12p, 12q, 16p, 17p, 17q, 19p, 20p, 20q, and 21q, and losses of 1p, 2p, 6q11.1-q16.3, 6q21-q22.1, 9p, 11p, 15q, and 19q were more prevalent in MPCs. High-level gains/amplifications of 8p12-p11, 8q12, 8q13, 8q21, 8q23, 8q24, 17q21, 17q23, and 20q13 were significantly associated with MPCs. A comparison between 24 MPCs and a series of 48 grade and ER-matched IDC-NSTs revealed that high cyclin D1 expression, high proliferation rates, and MYC (8q24) amplification were significantly associated with MPCs. Our results demonstrate that MPCs have distinct histological features and molecular genetic profiles supporting the contention that they constitute a distinct pathological entity.
Collapse
Affiliation(s)
- C Marchiò
- The Breakthrough Breast Cancer Research Centre--Institute of Cancer Research, London, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Reis-Filho JS, Natrajan R, Vatcheva R, Lambros MBK, Marchió C, Mahler-Araújo B, Paish C, Hodi Z, Eusebi V, Ellis IO. Is acinic cell carcinoma a variant of secretory carcinoma? A FISH study using ETV6'split apart' probes. Histopathology 2008; 52:840-6. [PMID: 18462362 DOI: 10.1111/j.1365-2559.2008.03046.x] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2023]
Abstract
AIMS Acinic cell carcinomas (ACCs) and secretory carcinomas (SCs) of the breast are rare, low-grade malignancies that preferentially affect young female patients. Owing to the morphological and immunohistochemical similarities between these lesions, they have been proposed to be two morphological variants of the same entity. It has been demonstrated that SCs of the breast consistently harbour the t(12;15)ETV6-NTRK3 translocation. The aim was to determine whether ACCs also harbour ETV6 gene rearrangements and are thus variants of SCs. METHODS AND RESULTS Using the ETV6 fluorescence in situ hybridization DNA Probe Split Signal (Dako), the presence of ETV6 rearrangements in three SCs and six ACCs was investigated. Cases were considered as harbouring an ETV6 gene rearrangement if >10% of nuclei displayed 'split apart signals' (i.e. red and green signals were separated by a distance greater than the size of two hybridization signals). Whereas the three SCs displayed ETV6 split apart signals in >10% of the neoplastic cells, no ACC showed any definite evidence of ETV6 gene rearrangement. CONCLUSIONS Based on the lack of ETV6 rearrangements in ACCs, our results strongly support the concept that SCs and ACCs are distinct entities and should be recorded separately in breast cancer taxonomy schemes.
Collapse
Affiliation(s)
- J S Reis-Filho
- Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Ailawadhi S, Derby L, Natrajan R, Reid ME, Ramnath N. Erlotinib for metastatic non-small cell lung cancer (mNSCLC): First, second or third line setting—Does it matter? A single institution experience. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.19083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Natrajan R, Warren W, Messahel B, Reis-Filho JS, Brundler MA, Dome JS, Grundy PE, Vujanic G, Pritchard-Jones K, Jones C. Complex patterns of chromosome 9 alterations including the p16INK4a locus in Wilms tumours. J Clin Pathol 2007; 61:95-102. [PMID: 17369505 DOI: 10.1136/jcp.2007.047159] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BACKGROUND Previous data implicating genetic and epigenetic events on chromosome 9, including the CDKN2A/2B locus, as molecular predictors of Wilms tumour relapse, have been conflicting. AIMS To clarify this using genome-wide and focused molecular genetic analysis. METHODS Microarray-based comparative genomic hybridisation (aCGH) using genome-wide coverage was applied to 76 favourable histology Wilms tumours. Additional investigation of the 9p21 locus was carried out using loss of heterozygosity (LOH) and fluorescence in situ hybridisation (FISH), as well as immunohistochemistry for CDKN2A/p16(INK4a) on a paediatric renal tumour tissue microarray. RESULTS Approximately half of the tumours were found to show chromosome 9 copy number changes. Those cases which harboured alterations comprised at least four distinct patterns: gain of the entire chromosome, loss of 9p, gain of 9q34, or a more complex combination of gains/losses. None of these tumour groups showed any statistically significant correlation with clinicopathological variables. Deletion mapping of 9p by LOH revealed several regions of overlap, including the CDKN2A/2B locus in 4/34 (11.8%) tumours, which was confirmed to represent hemizygous deletions by FISH. CDKN2A/p16(INK4a) protein expression was predominantly negative in Wilms tumours as assessed by immunohistochemistry on a tissue array, reflecting the expression pattern in normal kidney. However, 38/236 (16.1%) non-anaplastic Wilms tumours, 4/9 (44.4%) anaplastic Wilms tumours, 5/7 (71.4%) rhabdoid tumours of the kidney, and 4/10 (40%) clear cell sarcomas of the kidney showed nuclear CDKN2A/p16(INK4a )immunoreactivity. CONCLUSIONS These data reveal the complex nature of genetic alterations on chromosome 9 in Wilms tumours, but do not provide evidence for their involvement in or association with treatment failure.
Collapse
Affiliation(s)
- R Natrajan
- Paediatric Oncology, Institute of Cancer Research/Royal Marsden NHS Trust, Sutton, UK
| | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Natrajan R, Williams RD, Hing SN, Mackay A, Reis-Filho JS, Fenwick K, Iravani M, Valgeirsson H, Grigoriadis A, Langford CF, Dovey O, Gregory SG, Weber BL, Ashworth A, Grundy PE, Pritchard-Jones K, Jones C. Array CGH profiling of favourable histology Wilms tumours reveals novel gains and losses associated with relapse. J Pathol 2006; 210:49-58. [PMID: 16823893 DOI: 10.1002/path.2021] [Citation(s) in RCA: 97] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Despite the excellent survival of Wilms tumour patients treated with multimodality therapy, approximately 15% will suffer from tumour relapse, where response rates are markedly reduced. We have carried out microarray-based comparative genomic hybridisation on a series of 76 Wilms tumour samples, enriched for cases which recurred, to identify changes in DNA copy number associated with clinical outcome. Using 1Mb-spaced genome-wide BAC arrays, the most significantly different genomic changes between favourable histology tumours that did (n = 37), and did not (n = 39), subsequently relapse were gains on 1q, and novel deletions at 12q24 and 18q21. Further relapse-associated loci included losses at 1q32.1, 2q36.3-2q37.1, and gain at 13q31. 1q gains correlated strongly with loss of 1p and/or 16q. In 3 of 11 cases with concurrent 1p(-)/1q(+), a breakpoint was identified at 1p13. Multiple low-level sub-megabase gains along the length of 1q were identified using chromosome 1 tiling-path arrays. One such recurrent region at 1q22-q23.1 included candidate genes RAB25, NES, CRABP2, HDGF and NTRK1, which were screened for mRNA expression using quantitative RT-PCR. These data provide a high-resolution catalogue of genomic copy number changes in relapsing favourable histology Wilms tumours.
Collapse
MESH Headings
- Chromosome Aberrations
- Chromosome Deletion
- Chromosomes, Human, Pair 1/genetics
- Chromosomes, Human, Pair 16/genetics
- Chromosomes, Human, Pair 8/genetics
- DNA, Neoplasm/genetics
- Genes, Wilms Tumor/physiology
- Humans
- Kidney Neoplasms/genetics
- Kidney Neoplasms/pathology
- Neoplasm Recurrence, Local/genetics
- Oligonucleotide Array Sequence Analysis/methods
- RNA, Messenger/analysis
- RNA, Neoplasm/analysis
- Treatment Outcome
- Wilms Tumor/genetics
- Wilms Tumor/pathology
Collapse
Affiliation(s)
- R Natrajan
- Paediatric Oncology, Institute of Cancer Research/Royal Marsden NHS Trust, Sutton, Surrey SM2 5NG, UK
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Natrajan R, Little SE, Sodha N, Reis-Filho JS, Mackay A, Fenwick K, Ashworth A, Perlman EJ, Dome JS, Grundy PE, Pritchard-Jones K, Jones C. Analysis by array CGH of genomic changes associated with the progression or relapse of Wilms' tumour. J Pathol 2006; 211:52-9. [PMID: 17103382 DOI: 10.1002/path.2087] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Despite aggressive salvage regimens, approximately half of all children who suffer a Wilms' tumour recurrence will die of their disease. Although there are increasing data on molecular genetic prognostic factors present in the tumour at diagnosis, there is little information regarding the molecular events that occur with Wilms' tumour progression and relapse. In the present study, microarray-based comparative genomic hybridization (aCGH) analysis has been carried out on 58 Wilms' tumour samples, which included 38 untreated primary and 20 recurrent tumours. A higher degree of copy number changes was observed in the recurrent tumours (33.0% genomic clones) than in the primary tumour (21.2%). Paired analysis highlighted the acquisition of 15q gain with high levels of IGF1R expression in the tumour recurrence in two cases. The most statistically significant abnormality acquired between diagnosis and relapse was loss of 17p. One case that experienced 17p loss was classified as favourable histology at diagnosis, but exhibited diffuse anaplasia at recurrence and had a homozygous TP53 deletion. Another instructive case with a constitutional 11p13 deletion presented with bilateral tumours and suffered two subsequent recurrences in the left kidney. A somatic WT1 mutation was found only in the right kidney tumour, while the constitutional 11p13 deletion was the only abnormality detected in the initial left kidney tumour by aCGH. The two subsequent relapses in the left kidney contained an accumulation of additional genetic alterations, including an independent WT1 mutation.
Collapse
Affiliation(s)
- R Natrajan
- Paediatric Oncology, Institute of Cancer Research/Royal Marsden NHS Trust, Sutton, UK
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Abstract
The effect of cigarette smoke and nicotine on duodenal mucosal bicarbonate secretion (DMBS) was studied in rats. Cigarette smoke but not intravenous nicotine administered acutely to anesthetized rats via a tracheostomy tube stimulated DMBS by 47 +/- 6%. The increase was neurally mediated via atropine-sensitive postganglionic cholinergic neurons. Introduction of cigarette smoke after the infusion of vasoactive intestinal peptide and porcine histidine isoleucine (PHI) also caused a delayed increase in DMBS. However, the magnitude of this increase was similar to that seen in control non-peptide-infused rats. The increase in bicarbonate secretion predominantly involved Brunner's glands. Rats exposed to cigarette smoke for 4 and 8 days before direct instillation of smoke via tracheostomy tube did not show any increase in their DMBS. These studies indicate that in the rat, cigarette smoke increases DMBS, most likely secreted by the Brunner's glands. The increase is neurally mediated via atropine-sensitive postganglionic cholinergic neurons. Gastroenteric neuropeptides do not exert any influence on cigarette smoke-mediated DMBS secretion in the rat. Unlike acute exposure to cigarette smoke, chronic exposure (4 and 8 days) of rats to cigarette smoke abolishes increase in DMBS induced by subsequent exposure to cigarette smoke. This last observation may, in part, may explain the tendency of chronic smokers who have duodenal bulb ulcers to show greater propensity to higher rate of recurrence and protracted healing.
Collapse
Affiliation(s)
- S Murthy
- Division of Gastroenterology and Hepatology, Allegheny University of the Health Sciences University, Philadelphia, PA 19102-1192, USA.
| | | | | |
Collapse
|